Actavis May Need To Rethink Nebivolol/Valsartan Claim After Negative Panel Vote
This article was originally published in The Pink Sheet Daily
Executive Summary
The sponsor argues that the fixed-dose antihypertensive combo offers better efficacy and tolerability than either compound as solo therapy, but FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 6-4 against approval.